Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41) | Starlite/ChEMBL | References |
Homo sapiens | integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) | References |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | survival motor neuron protein 1 | 0.0271 | 0.2571 | 0.2926 |
Echinococcus multilocularis | integrin alpha 3 | 0.0142 | 0.1113 | 0.0696 |
Brugia malayi | Integrin alpha cytoplasmic region family protein | 0.014 | 0.1092 | 0.1263 |
Loa Loa (eye worm) | integrin beta-2 | 0.0378 | 0.3789 | 0.492 |
Brugia malayi | Integrin beta pat-3 precursor | 0.0378 | 0.3789 | 0.4828 |
Echinococcus multilocularis | fructose 1,6 bisphosphatase 1 | 0.0724 | 0.7701 | 0.7593 |
Loa Loa (eye worm) | fructose-1,6-bisphosphatase | 0.0724 | 0.7701 | 1 |
Echinococcus granulosus | integrin alpha 3 | 0.0142 | 0.1113 | 0.0916 |
Echinococcus granulosus | fructose 16 bisphosphatase 1 | 0.0724 | 0.7701 | 1 |
Schistosoma mansoni | integrin beta subunit | 0.0223 | 0.2031 | 0.2637 |
Brugia malayi | Kelch motif family protein | 0.0057 | 0.0162 | 0.0034 |
Trypanosoma cruzi | fructose-1,6-bisphosphatase, cytosolic, putative | 0.0724 | 0.7701 | 1 |
Echinococcus multilocularis | integrin beta 2 | 0.028 | 0.268 | 0.2337 |
Loa Loa (eye worm) | hypothetical protein | 0.0102 | 0.0664 | 0.0863 |
Leishmania major | 0.0724 | 0.7701 | 0.5 | |
Onchocerca volvulus | 0.0055 | 0.0136 | 0.5 | |
Schistosoma mansoni | survival motor neuron protein | 0.0055 | 0.0136 | 0.0177 |
Echinococcus multilocularis | survival motor neuron protein 1 | 0.0271 | 0.2571 | 0.2222 |
Trypanosoma cruzi | fructose-1,6-bisphosphatase, cytosolic, putative | 0.0724 | 0.7701 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0055 | 0.0136 | 0.0177 |
Loa Loa (eye worm) | hypothetical protein | 0.0271 | 0.2571 | 0.3339 |
Schistosoma mansoni | integrin alpha | 0.0185 | 0.16 | 0.2078 |
Trypanosoma brucei | fructose-1,6-bisphosphatase | 0.0724 | 0.7701 | 1 |
Brugia malayi | Integrin alpha pat-2 precursor | 0.0185 | 0.16 | 0.1935 |
Loa Loa (eye worm) | hypothetical protein | 0.0145 | 0.1152 | 0.1496 |
Loa Loa (eye worm) | hypothetical protein | 0.0057 | 0.0162 | 0.0211 |
Loa Loa (eye worm) | integrin alpha pat-2 | 0.0285 | 0.2731 | 0.3546 |
Loa Loa (eye worm) | hypothetical protein | 0.014 | 0.1092 | 0.1418 |
Schistosoma mansoni | integrin alpha-ps | 0.0083 | 0.0449 | 0.0583 |
Brugia malayi | fructose-1,6-bisphosphatase | 0.0724 | 0.7701 | 1 |
Brugia malayi | hypothetical protein | 0.0271 | 0.2571 | 0.3218 |
Brugia malayi | hypothetical protein | 0.0057 | 0.0162 | 0.0034 |
Schistosoma mansoni | fructose-16-bisphosphatase-related | 0.0724 | 0.7701 | 1 |
Echinococcus granulosus | integrin beta 2 | 0.028 | 0.268 | 0.3077 |
Loa Loa (eye worm) | kelch domain-containing protein family protein | 0.0057 | 0.0162 | 0.0211 |
Toxoplasma gondii | fructose-bisphospatase II | 0.0724 | 0.7701 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = 0.11 uM | Concentration required to reduce binding of fibrinogen to purified Fibrinogen Receptor by 50% using ELISA | ChEMBL. | 9207949 |
IC50 (binding) | = 0.11 uM | Concentration required to reduce binding of fibrinogen to purified Fibrinogen Receptor by 50% using ELISA | ChEMBL. | 9207949 |
IC50 (functional) | = 1.2 uM | Ability to block Glyocoprotein IIb-IIIa was measured by inhibiting ADP induced human platelet aggregation (5 uM) | ChEMBL. | 9207949 |
IC50 (functional) | = 1.2 uM | Ability to block Glyocoprotein IIb-IIIa was measured by inhibiting ADP induced human platelet aggregation (5 uM) | ChEMBL. | 9207949 |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | 9207949 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.